BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Obudanersen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Obudanersen\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06914609-10803@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Obudanersen: Phase 3 readout est. (NCT06914609)
DESCRIPTION:Obudanersen\, phase 3\, Angelman Syndrome.\nStudy: REVEAL: A Ph
 ase 3 Study of Obudanersen (ION582) in Angelman Syndrome\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/obudanersen#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06914609
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782827-10803@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obudanersen: Phase 3 readout est. (NCT07782827)
DESCRIPTION:Obudanersen\, phase 3\, Angelman Syndrome.\nStudy: CHAMPION: A 
 Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Child
 ren and Adults With Angelman Syndrome (AS)\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obudanersen
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 82827
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05127226-10803@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Obudanersen: Phase 1/2 readout est. (NCT05127226)
DESCRIPTION:Obudanersen\, phase 1/2\, Angelman Syndrome.\nStudy: HALOS: A S
 afety\, Tolerability\, Pharmacokinetics and Pharmacodynamics Study of Mult
 iple Ascending Doses of ION582 in Participants With Angelman Syndrome\nEst
 imated primary completion: March 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obudanersen#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05127226
URL:https://assetmemo.bio/drug/obudanersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
